The Microdose Array Print (MAP) Technology has shown potential in clinical trials, providing the possibility of more accurate ocular drug delivery than traditional eye droppers

Eyenovia

Eyenovia

Eyenovia

NEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE) — While medical devices have seen incredible advancements over the last 100 years, ocular drug shipping systems have seen minimal progress; the particular standard eye dropper used today has gone largely unchanged in the last century.   Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing a pipeline associated with late-stage microdose array print (MAP™) therapeutics, is developing one of the first microdosing systems that aims to improve the particular overall patient experience and streamline practice flow by facilitating digital delivery associated with eye medications.

The investigational delivery device is currently only utilized in clinical study settings and has shown promise in delivering cleaner plus more efficient ocular drug delivery. “The proprietary Eyenovia device takes a novel approach to administering vision medication via microdosing and does it in a way that should improve the patient experience, ” said Michael Rowe, CEO of Eyenovia. “Traditional eye droppers are cumbersome, inaccurate, and prone in order to contamination. Even when handled with care, there’s still a significant likelihood that medication patients are paying for gets wasted due to missing drops. ”

The gadget is uniquely designed with no protruding parts and a recessed nozzle to not touch patients’ eyes, reducing the likelihood of infection. Eyenovia also expects a more gentle dosing experience in order to create a fundamental paradigm shift within eye treatment.

Eye drop innovation offers stagnated, in part due to changing medical device regulations that complicate patient access to innovative products. Safety takes precedence in the medical device industry; however , as electronic innovation leaps ahead associated with bureaucratic regulatory bodies, regulators are challenged to keep pace with the cutting-edge new products that push the boundaries of technology.

Whilst the world of healthcare looked significantly different 100 years ago, similar paradigm shifts in healthcare technology through innovations like pacemakers, cochlear implants, 3-D printed body parts, and artificial hearts revolutionized their respective industries, greatly improving quality of life and individual care. With a market share valued at  roughly €100 billion in Europe , medical devices make up 7. 5% associated with healthcare expenditure in most publicly funded healthcare techniques, and the American ecosystem is taking notice.

As United states private venture capital makes inroads into the digital health market, the total capital investment in healthcare devices has  increased by the factor of five , which portends a promising future for improved patient care. Medical technologies device advancement is only expected to increase over the particular next five years, plus Eyenovia will be one of those industry leaders in championing innovation.

“We’re proud to be innovating in this space where we possess the potential to make lives easier for millions associated with Americans and people worldwide suffering from chronic attention conditions, inch adds Rowe.

For more information, visit  eyenovia. com .

About Eyenovia, Incorporation.

Eyenovia , Inc. is usually a pre-commercial ophthalmic technology company having a pipeline of microdose array print (MAP™) therapeutics. Eyenovia is presently focused on the late-stage development of microdosed medications with regard to mydriasis, presbyopia and myopia progression. To find out more, visit  www.eyenovia.com .

Forward-Looking Statements

Except for historical information, all associated with the statements, expectations plus assumptions contained in this press release are forward-looking claims. Forward-looking statements include, but are not limited to, claims that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technologies. These statements are based on current expectations, estimates and projections about our own business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes plus results may, and within some cases are likely to, differ materially through what is expressed or forecasted within the forward-looking statements because of to numerous factors discussed from time to period in documents which we file with the U. S. Securities and Exchange Commission. In addition , such claims could be affected by risks and questions related to, among other things: risks associated with our medical trials, including, but not really limited to, the particular costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19), timing, progress plus results of such tests; the time of, and our ability to submit applications regarding, obtaining plus maintaining regulating approvals for the product candidates; the potential impacts associated with COVID-19 upon our supply chain; the advantages of our item candidates and platform technology; the rate plus degree of market acceptance and clinical utility of our product candidates; the estimates regarding the possible market opportunity for our item candidates; reliance on third parties to develop and commercialize our product candidates; the ability of us and our partners in order to timely develop, implement plus maintain manufacturing, commercialization and marketing capabilities and strategies for our item candidates; intellectual property dangers; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact associated with these changes on our own ability to obtain regulatory approval for our products; and the competitive position. Any forward-looking statements speak only as of the particular date on which they are usually made, plus except because may be required under applicable securities laws. Eyenovia does not undertake any obligation to update any forward-looking statements.

Contact Information:
Norbert Lowe
Vice President, Commercial Operations
[email protected] com

Buse Kayar
[email protected] possuindo

Related Images

Image 1: Eyenovia

Eyenovia

This content was issued via the

Leave a Reply

Your email address will not be published. Required fields are marked *